Form 4: BioCardia CEO Altman Reports RSU Vesting, Option Grant

BioCardia's President and CEO, Peter Altman, reported the vesting of restricted stock units and the grant of new stock options.

Summary

• Peter Altman, President and CEO, and a Director of BioCardia, Inc. (BCDA), reported transactions related to his beneficial ownership.
• On December 8, 2025, 106,588 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of common stock, awarded as compensation.
• Concurrently, 56,484 shares of common stock were withheld by the Issuer to satisfy income tax, withholding, and remittance obligations related to the RSU vesting, which does not represent a sale by Mr. Altman.
• Following these transactions, Mr. Altman beneficially owns 266,866 shares of common stock directly.
• Additionally, on December 8, 2025, Mr. Altman was granted 38,000 stock options with an exercise price of $1.37 per share.
• These options will vest as to 1/48th of the shares on January 8, 2026, and each month thereafter, subject to his continued service.
• The options have an expiration date of December 8, 2035.
• Following the option grant, Mr. Altman beneficially owns 90,215 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a 'disposition' of shares, it's for tax purposes related to compensation, not a market sale. The grant of new options and vesting of RSUs are standard executive compensation practices that align management's interests with shareholders, indicating continued commitment.

Positives

• The vesting of 106,588 restricted stock units represents a form of compensation for the CEO, aligning his interests with shareholders.
• The grant of 38,000 new stock options further incentivizes the CEO for long-term performance and continued service to the company.

Negatives

• The disposition of 56,484 shares for tax withholding, while not a direct sale, reduces the CEO's direct shareholding post-vesting.

Future Outlook

The stock options granted to the CEO are structured to vest monthly over a period, indicating a long-term incentive plan tied to his continued service through December 2035.

Industry Context

This filing is a routine insider transaction report, common across all industries, reflecting executive compensation and equity incentive plans. It does not provide specific insights into broader industry trends for the biotechnology or medical device sector.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as executive compensation is a standard practice across many industries, including biotechnology, to align management incentives with shareholder value creation.
• The vesting schedule for the options (1/48th monthly) is a common approach to ensure long-term retention and performance.

Stakeholder Impact

• Shareholders: The compensation structure, including RSU vesting and option grants, aims to align the CEO's long-term interests with shareholder value creation.
• Employees: This filing specifically details executive compensation and does not directly impact other employees, though it reflects the company's overall compensation philosophy.

Next Steps

• The granted stock options will begin vesting on January 8, 2026, and continue monthly thereafter.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (RSU vesting and option grants) and tax-related share withholding. It does not contain information that would fundamentally alter the investment thesis for BioCardia, Inc. While it shows continued alignment of management's interests, it's not a catalyst for a 'buy' or 'sell' recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial news.

Keywords

BioCardia, BCDA, Peter Altman, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Options, Executive Compensation, Corporate Governance